Orexigen and FDA find way forward for obesity drug Contrave
Shares of US drug developer Orexigen Therapeutics (Nasdaq: OREX) 86% to $2.74 in extended trading yesterday, after the company said that a recent meeting with senior officials in Food and Drug Administration's Office of New Drugs (OND) had resulted in establishing a pathway to resubmission of the New Drug Application for its obesity drug candidate Contrave (bupropion/naltrexone).
The move bodes well for the weight-loss drug market - where no new prescription medicine has been cleared by the FDA since 1999 - and follows the news last week that fellow obesity drug developer Vivus has also found a way forward for its candidate Qnexa (phentermine/topiramate (The Pharma Letter September 16).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze